Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Usnoflast Administered to Adult Subjects With ALS

NCT07023835 is registered in ClinicalTrials.gov with Zydus Therapeutics Inc. as lead sponsor.

NCT NCT07023835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07023835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Usnoflast Administered to Adult Subjects With ALS
Lead sponsor
Zydus Therapeutics Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
September 17, 2025
Completion date
October 31, 2028
Enrollment
240 (estimated)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis (als)